Latest news with #QTImagingHoldings
Business Wire
2 days ago
- Health
- Business Wire
QT Imaging Launches QTviewer 2.8 to Enhance Clinical Efficiency and Diagnostic Accuracy
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce the launch of its latest QTviewer™, version 2.8. QTviewer stores and displays the QTscan™ images generated by the Company's U.S. FDA-cleared QTI Breast Acoustic CT™ scanner, the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation — setting a new standard for safe and repeatable monitoring. Key features of QTviewer 2.8 include: Effortless, Stateless DICOM (Digital Imaging and Communications in Medicine) Viewing: QTviewer 2.8 enables instant access to QTscan studies without a preconfigured database — ideal for remote reads, portable drives, or low-resource environments. This also supports direct PACS (Picture Archiving and Communication System) integration where available. Real-Time Lesion Doubling Time Analysis: Integrated tool allows clinicians to assess lesion growth within the standard reading workflow — enhancing monitoring of disease progression or treatment response. Unlike conventional methods, QTI's technology enables fully quantitative, volumetric analysis without the need for contrast agents or ionizing radiation. New RGB Visualization Modes: Enables interpretation of both anatomical structures and quantitative data, supporting diagnostic and research use cases alike. The RGB mode incorporates speed of sound mapping, providing additional visual representation of tissue composition and imaging findings — an essential capability for advancing our research into lesion characterization and AI-driven classification. Advanced Multi-Series Comparison: Radiologists can now view multiple series from the same study in parallel windows, improving anatomical and temporal comparisons. Optimized Viewport Layouts for Radiology Workstations: Vertical orientation and multi-monitor support improve ergonomics and diagnostic clarity for stackable and long-axis views. Secure License Management for Enterprise Use: PC-based license key verification ensures secure, compliant deployment across hospital and academic systems. Improved Stability & Usability: Backend upgrades streamline loading, enhance compatibility, and support quick launches from file associations or command line; and Reinforced Diagnostic Workflow: QTviewer 2.8 provides automatic recognition of image types, such as speed-of-sound, attenuation, and reflection, ensuring seamless workflow and consistent interpretation. 'This is an exciting time for our team as we enter into a period of anticipated rapid growth, driven by continuous innovation like our recent release of image reconstruction software, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency, and this enhanced generation of QTviewer,' said QTI's Chief Science Officer, Dr. Bilal Malik. 'By providing radiologists and clinical partners with a growing portfolio of enabling, intuitive support tools, QTI aims to expand access to medical imaging while ensuring superior patient experience and improving health outcomes.' Transforming QTI into a precision imaging AI company is a key pillar of the Company's growth strategy. To that end, beyond today's announcement, the QTI team continues to innovate by not only developing proprietary AI/ML tools designed to accelerate image processing and reduce scanning time, but also conducting AI/ML projects which will be viewed/integrated in the QTviewer in the future. About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of QTviewer and the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including transforming it into a precision imaging AI company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, clinical studies, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Business Wire
08-07-2025
- Business
- Business Wire
QT Imaging Bolsters Medical and Clinical Leadership with Senior Appointments to Further Drive Innovation and Clinical Adoption
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce the appointments of Elaine Iuanow, MD, as Chief Medical Officer ('CMO') and Kim Du as Senior Director of Clinical Operations. These additions to the leadership team significantly enhance the Company's medical and clinical capabilities as QTI expands its clinical studies as well as the development of AI-driven lesion classification and second-read decision support tools alongside the commercialization of its FDA-cleared QTI Breast Acoustic CT™ scanner. 'On behalf of the entire team, I'm thrilled to welcome Elaine and Kim to QT Imaging,' said Dr. Raluca Dinu, CEO of QTI. 'They bring deep clinical expertise and leadership that will be critical as we enter our next chapter: expanding our evidence base, driving reimbursement, and transforming QTI into a precision imaging AI company. Their contributions will help us advance not only the clinical adoption of our platform but also a new generation of AI-enhanced diagnostic tools that support improved outcomes, earlier detection, and broader access.' As CMO, Dr. Iuanow will lead clinical strategy and development, regulatory engagement, and external partnerships with thought leaders and institutions, while supporting QTI's broader strategic focus of AI-driven precision imaging and diagnostic innovation. A board-certified radiologist with more than two decades of experience in women's health, breast imaging, and academic medicine, Dr. Iuanow has held clinical positions at Beth Israel Deaconess Medical Center/Harvard Medical School and Brigham and Women's Community Radiology Division. She completed her residency at Tufts Medical Center and a breast imaging fellowship at Faulkner-Sagoff/Brigham and Women's Hospital. 'From a patient's perspective, breast imaging should be accurate, comfortable, and stress-free,' said Dr. Iuanow. 'QTI's unique Breast Acoustic CT™ technology combines true 3D anatomical and quantitative imaging with the power of artificial intelligence. It has the potential to become a highly accessible and affordable alternative to MRI—especially for the 50% of U.S. women between 40–74 with dense breast tissue 1. I'm honored to join a team committed to fundamentally improving diagnostic confidence and patient experience.' Dr. Iuanow added: 'With our multi-center, evidence-based clinical trial portfolio, QTI will be studied as an alternative to MRI for imaging high-risk women and for breast cancer management in the neoadjuvant setting, as well as a potential platform for future minimally invasive radiologic treatment of breast cancer. I'm especially excited about the development of AI-driven tools that automate findings classification and deliver consistent second-read decision support.' Ms. Du joins QTI with over fifteen years of medical product development experience. Most recently, she served as Senior Director of Clinical Operations for Avisi Technologies, a clinical-stage ophthalmic device company. Prior to Avisi, she held a variety of clinical research management roles at leading medical device innovators, such as Alcon, Avinger and SentreHEART. Ms. Du earned a Bachelor of Science, Bioengineering and Biomedical Engineering from the University of Washington in 2007. As Senior Director of Clinical Operations, Ms. Du is responsible for the strategic leadership and execution of the Company's clinical trials across all phases of development. She oversees trial planning, site and vendor management, Good Clinical Practice (GCP) compliance, data integrity, and team performance to help ensure the successful execution of studies that support additional regulatory approvals, product adoption, and commercialization. Sources 1 About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, clinical studies, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Business Wire
04-07-2025
- Business
- Business Wire
QT Imaging to Hold Virtual 2025 Annual Meeting of Stockholders on August 19
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced that its 2025 Annual Meeting of Stockholders will be held as a virtual meeting on Tuesday, August 19, 2025, at 1:00 p.m. EDT (10:00 a.m. PDT). Stockholders of record at the close of business on July 16, 2025 shall be entitled to vote at the 2025 Annual Meeting. Information about the virtual meeting webcast and instructions for how stockholders can participate in the 2025 Annual Meeting will be included in the definitive proxy statement to be filed with the Securities and Exchange Commission and will be available on the "Investors" section of QT Imaging's website at About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the date of its annual meeting of stockholders. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Business Wire
25-06-2025
- Business
- Business Wire
QT Imaging Leverages NVIDIA L40 GPU Acceleration to Power its Next-Gen Breast Imaging Reconstruction Software
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB:QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce its latest image reconstruction software update release, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency. The software update was developed leveraging NVIDIA's L40 GPU, powered by the Ada Lovelace architecture. The U.S. FDA-cleared QTI Breast Acoustic CT™ scanner is the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation. Despite the processing speed gains achieved via the version 4.4.0 software update, QTscan breast image fidelity and diagnostic accuracy are uncompromised, and image quality remains best-in-class, with a resolution similar to magnetic resonance imaging (MRI). Designed to meet the needs of busy breast imaging centers, the software update ensures minimal downtime and seamless integration into existing workflows. Accordingly, it enhances scalability for institutions expanding their QTI breast screening programs, ensuring consistent performance across increasing patient volumes. 'This latest software release reflects direct input from radiologists and clinical partners, underscoring our commitment to continuous innovation based on real-world use,' said QTI's CEO, Dr. Raluca Dinu. 'Faster image availability enables radiologists to review and interpret QTI scans more quickly, supporting earlier clinical decision-making. And accelerated processing reduces wait times for results, contributing to a smoother and more reassuring patient journey.' The QTI team continues to innovate by leveraging proprietary machine learning algorithms not only to accelerate image processing via the version 4.4.0 software update, but also to actively reduce scanning time — a key focus area in ongoing development. Version 4.4.0 is optimized for systems utilizing NVIDIA's L40 GPUs and remains fully backward-compatible with earlier QTI system hardware, ensuring broad accessibility through scalable, software-driven architecture. About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, including the software update, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Business Wire
15-05-2025
- Business
- Business Wire
QT Imaging Holdings Delivers Its Breast Imaging Scanner to Innovative Radiology in Des Moines, Iowa
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB:QTIH) a medical device company engaged in research, development, and commercialization of innovative body imaging systems is proud to announce the delivery and installation of its QT Imaging Breast Acoustic CT™ Scanner at Innovative Radiology, led by Dr. John Tentinger in Des Moines, Iowa. This installation brings QT Imaging's radiation-free, 3D breast imaging technology to patients in Iowa for the first time. QT Imaging's breast imaging scanner uses proprietary low-frequency ultrasound to generate high-resolution, 3D images of breast tissue—without ionizing radiation or compression. This non-invasive approach provides a safer, more comfortable, high resolution, and repeatable imaging option, particularly for patients with dense breast tissue. 'We are excited to bring our breast imaging technology to Des Moines and to partner with Dr. Tentinger and Innovative Radiology,' said Dr. Raluca Dinu, CEO of QT Imaging Holdings. 'This collaboration reflects our shared vision of advancing women's health by making high-quality, patient-friendly imaging more accessible. We're also grateful to our distribution partner, NXC Imaging, for facilitating this important connection and supporting the successful deployment of our technology.' Dr. Tentinger, a respected board-certified radiologist, leads Innovative Radiology with a focus on furthering access to precise imaging and accurate diagnostic assessments to ensure that patients have a clear road map to optimally navigate their health journey. In addition to the newly installed QT Imaging Breast Acoustic CT Scanner, his facility is equipped with a full suite of imaging technologies, including mammography, MRI, CT, ultrasound, and X-ray—ensuring comprehensive diagnostic capabilities under one roof. The addition of QTI's technology further enhances the clinic's commitment to offering the latest in imaging innovation. 'Our practice is dedicated to improving diagnostic outcomes while prioritizing patient experience,' said Dr. Tentinger. 'The QT Imaging Breast Acoustic CT Scanner allows us to offer a safer, gentler, yet highly detailed breast imaging option that many patients will prefer. We're proud to be the first in Iowa to offer this technology.' About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. About Innovative Radiology, Inc. Innovative Radiology specializes in precision imaging to optimize patient outcomes. Utilizing state-of-the-art imaging equipment, it employs highly skilled radiologists and technologists who provide detailed and timely diagnostic assessments for medical providers, so they are empowered to make confident healthcare decisions for their patients. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
